The potential sale of its 88% stake in Bausch + Lomb could generate billions for creditors and shareholders of the indebted ...
Bausch Health has recently changed its strategy for Bausch + Lomb, looking to sell the segment which has a market capitalization of nearly $8 billion. The potential sale of Bausch + Lomb is a break ...
In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...
The FDA granted approval to the enVista Envy full range of vision IOLs following Canadian approval in May 2024.
Bausch Health Companies Inc. ( NYSE:BHC ) shareholders should be happy to see the share price up 26% in the last ...